Cd8(+) T-Cell Responses to Adeno-Associated Virus Capsid in Humans
The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Hepatic adeno-associated virus (AAV)-serotype 2 mediated gene transfer results in transgene product expression that is sustained in experimental animals but not in human subjects. We hypothesize that this is caused by rejection of transduced hepatocytes by AAV capsid-specific memory CD8(+) T cells reactivated by AAV vectors. Here we show that healthy subjects carry AAV capsid-specific CD8(+) T cells and that AAV-mediated gene transfer results in their expansion. No such expansion occurs in mice after AAV-mediated gene transfer. In addition, we show that AAV-2 induced human T cells proliferate upon exposure to alternate AAV serotypes, indicating that other serotypes are unlikely to evade capsid-specific immune responses.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Detection of AAV components by the innate immune system also leads to the AAV-directed adaptive immune response and potential loss of transgene expression in transduced cells (Mingozzi et al., 2007; Xiang et al., 2020).”
From Gene Therapy-Associated Uveitis (GTAU): Understanding and mitigating the adverse immune response in retinal gene therapy (2025) · cites this paper as Mingozzi et al., 2007
In the citing paper
“Early successes in this field were initially dampened by reports of patients who developed vector insertion-related leukemias directly linked to the viral platform used for transgene delivery11–18.”
From Clonal selection of hematopoietic stem cells after gene therapy for sickle cell disease (2023) · cites this paper as [12]
In the citing paper
“Evidence from early clinical trials, along with subsequent laboratory studies, suggest that CD8+ T cell responses against AAV capsid target transduced hepatocytes (16–18).”
From Effect of CpG Depletion of Vector Genome on CD8+ T Cell Responses in AAV Gene Therapy (2021) · cites this paper as [17]
In the citing paper
“An early clinical trial for the treatment of hemophilia, via i.v. delivery of recombinant AAV (rAAV), resulted in robust CD8 T cell responses and the loss of transgene expression, which was later shown to be mediated by capsid-specific T cell responses.”
From Modulating immune responses to AAV by expanded polyclonal T-regs and capsid specific chimeric antigen receptor T-regulatory cells (2021) · cites this paper as [5]
In the citing paper
“Although AAV infection is non-pathogenic in humans, initial exposure induces humoral and cellular anti-capsid response that are reactive to rAAV due to capsid similarity (4, 5).”
From Immunomodulation in Administration of RAAV: Preclinical and Clinical Adjuvant Pharmacotherapies (2021) · cites this paper as [5]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Manno, C. S., Pierce, G. F., Arruda, V. R., Glader, B., Ragni, M., Rasko, J. J. E., Ozelo, M. C., Hoots, K., Blatt, P., Konkle, B., et al. (2006) · Nature Medicine · doi:10.1038/nm1358 · Cited by 2,163
Self-citationMemory CD8+ T cells vary in differentiation phenotype in different persistent virus infections
Appay, V., Dunbar, P. R., Callan, M., Klenerman, P., Gillespie, G. M. A., Papagno, L., Ogg, G. S., King, A., Lechner, F., Spina, C. A., et al. (2002) · Nature Medicine · doi:10.1038/nm0402-379 · Cited by 1,571
Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy
Gao, G.-P., Alvira, M. R., Wang, L., Calcedo, R., Johnston, J., & Wilson, J. M. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.182412299 · Cited by 1,520
Snyder, R. O., Miao, C., Meuse, L., Tubb, J., Donahue, B. A., Lin, H.-F., Stafford, D. W., Patel, S., Thompson, A. R., Nichols, T., et al. (1999) · Nature Medicine · doi:10.1038/4751 · Cited by 409
Mount, J. D., Herzog, R. W., Tillson, D. M., Goodman, S. A., Robinson, N., McCleland, M. L., Bellinger, D., Nichols, T. C., Arruda, V. R., Lothrop, C. D., et al. (2002) · Blood · doi:10.1182/blood.v99.8.2670 · Cited by 339
Self-citationHeparin binding directs activation of T cells against adeno-associated virus serotype 2 capsid
Vandenberghe, L. H., Wang, L., Somanathan, S., Zhi, Y., Figueredo, J., Calcedo, R., Sanmiguel, J., Desai, R. A., Chen, C. S., Johnston, J., et al. (2006) · Nature Medicine · doi:10.1038/nm1445 · Cited by 208
Wang, L., Nichols, T. C., Read, M. S., Bellinger, D. A., & Verma, I. M. (2000) · Molecular Therapy · doi:10.1006/mthe.2000.0031 · Cited by 176
Identification of mouse AAV capsid-specific CD8+ T cell epitopes
Sabatino, D. E., Mingozzi, F., Hui, D. J., Chen, H., Colosi, P., Ertl, H. C. J., & High, K. A. (2005) · Molecular Therapy · doi:10.1016/j.ymthe.2005.09.009 · Cited by 91
Self-citation
Research works printed but not linked: 1
- Muzyczka, N. & Berns, K.I. Parvoviridae: The Viruses and Their Replication, 2327–2359 (Lippincott Williams & Wilkins, Philadelphia, 2001).
Cited by
Items 501–600 of 765
Yang, C., Hao, F., He, J., Lu, T., Klein, R. L., Zhao, L., & Duan, W. (2016) · Human Gene Therapy · doi:10.1089/hum.2015.083 · Cited by 12
Saleün, S., Mas, C., Roy, A. L., Penaud‐Budloo, M., Adjali, O., Blouin, V., & Ebel, C. (2023) · European Biophysics Journal · doi:10.1007/s00249-023-01650-3 · Cited by 12
Janelidze, S., Nordström, U., Kügler, S., & Brundin, P. (2014) · The Journal of Gene Medicine · doi:10.1002/jgm.2779 · Cited by 12
“Moreover, some individuals carry AAV capsid-specific cytotoxic memory CD8 T cells [19].”
BackgroundLocke, M., Ussher, J. E., Mistry, R. M., Taylor, J. A., & Dunbar, P. R. (2011) · Tissue Engineering Part C Methods · doi:10.1089/ten.tec.2011.0153 · Cited by 13
Nair, N., Wolf, D. D., Nguyen, P. A., Pham, Q. H., Samara-Kuko, E., Landau, J., Blouse, G. E., Chuah, M., & VandenDriessche, T. (2021) · Blood · doi:10.1182/blood.2020006005 · Cited by 15
Arthritis Gene Therapy Trials Reach Phase II
Evans, C. H. (2010) · The Journal of Rheumatology · doi:10.3899/jrheum.100055 · Cited by 12
Blahetek, G., Lindner, B., Oti, M., Schön, C., & Strobel, B. (2025) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2025.101499 · Cited by 13
Phoenix rising: gene therapy makes a comeback
Limberis, M. P. (2012) · Acta Biochimica et Biophysica Sinica · doi:10.1093/abbs/gms036 · Cited by 14
Recent developments with advancing gene therapy to treat chronic infection with hepatitis B virus
Maepa, M. B., Jacobs, R., van den Berg, F. T., & Arbuthnot, P. B. (2020) · Current Opinion in HIV and AIDS · doi:10.1097/coh.0000000000000623 · Cited by 12
Intraosseous delivery of platelet-targeted factor VIII lentiviral vector in humanized NBSGW mice
Joo, J. H., Wang, X., Singh, S., Chen, C., Li, C., Adair, J. E., Kiem, H., Rawlings, D. J., & Miao, C. H. (2022) · Blood Advances · doi:10.1182/bloodadvances.2022008079 · Cited by 11
AAV mediated gene therapy for haemophilia B: From the early attempts to modern trials
Muczynski, V., & Nathwani, A. C. (2024) · Thrombosis Research · doi:10.1016/j.thromres.2020.12.033 · Cited by 11
Zinkernagel, M. S., McMenamin, P. G., Forrester, J. V., & Degli‐Esposti, M. A. (2011) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2011.04.001 · Cited by 11
Jin, Q., Qiao, C., Li, J., Li, J., & Xiao, X. (2019) · Gene Therapy · doi:10.1038/s41434-019-0107-2 · Cited by 11
Simmons, E. M., Wen, Y., Li, J., Qian, Y., Wong, L. C., Konrad, R. J., & Bivi, N. (2022) · Journal of Immunological Methods · doi:10.1016/j.jim.2022.113397 · Cited by 11
Immunosuppression Decreases Inflammation and Increases AAV6-hSERCA2a-Mediated SERCA2a Expression
Zhu, X., McTiernan, C. F., Rajagopalan, N., Shah, H., Fischer, D., Toyoda, Y., Letts, D. P., Bortinger, J., Gibson, G. A., Xiang, W., et al. (2012) · Human Gene Therapy · doi:10.1089/hum.2011.108 · Cited by 14
“Subsequent studies demonstrated the presence of CD8 + T cells reactive to AAV capsid epitopes (Mingozzi and High, 2007; Mingozzi et al. , 2007) and indicated that human hepatocytes containing even extremely low levels of MHC class I molecules loaded with AAV capsid-derived peptides are targets for…”
Vector-Mediated Antibody Gene Transfer for Infectious Diseases
Schnepp, B. C., & Johnson, P. R. (2015) · Advances in experimental medicine and biology · doi:10.1007/978-1-4939-2432-5_8 · Cited by 11
Adeno-Associated Virus Vectors: Versatile Tools for in vivo Gene Transfer
Zentilin, L., & Giacca, M. (2008) · KARGER eBooks · doi:10.1159/000125584 · Cited by 15
VandenDriessche, T., & Chuah, M. (2011) · Human Gene Therapy · doi:10.1089/hum.2011.221 · Cited by 11
“This decline could possibly be attributed to a vector dose–dependent AAV2 capsid-specific T-cell response that eliminated the FIX-transduced hepatocytes (Mingozzi et al ., 2007).”
Hareendran, S., Ramakrishna, B., & Jayandharan, G. R. (2016) · European Journal of Immunology · doi:10.1002/eji.201545867 · Cited by 10
Pekrun, K., Stephens, C. J., Gonzalez‐Sandoval, A., Goswami, A., Zhang, F., Tarantal, A. F., Blouse, G. E., & Kay, M. A. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.05.005 · Cited by 10
iPSC-hepatocyte organoids as a novel platform to predict AAV gene therapy efficacy
Berreur, E., Lazzaroni, G., Roth, C., Zihlmann, M., Stirn, M., Matheis, R., Xicluna, R., Breous-Nystrom, E., & Roth, A. B. (2025) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2025.101467 · Cited by 10
“14,15 Interestingly, these issues were absent in small animal models, as well as non-human primate models.”
Immune Toxicities in AAV Gene Therapy: Overview for Clinicians
Parajuli, S., Gallagher, T. L., & Flotte, T. R. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27073196 · Cited by 12
Bohlen, M. O., El-Nahal, H. G., & Sommer, M. A. (2019) · Frontiers in Neuroanatomy · doi:10.3389/fnana.2019.00084 · Cited by 11
Circumventing B Cell Responses to Allow for Redosing of Adeno-Associated Virus Vectors
Ertl, H. C. J. (2024) · Human Gene Therapy · doi:10.1089/hum.2023.162 · Cited by 10
Self-citationShen, J., Zhen, L. I., Liu, X., Zheng, M., Zhang, P., Chen, Y., Tian, Q., Tian, W., Kou, G., Cui, Y., et al. (2024) · Advanced Science · doi:10.1002/advs.202404274 · Cited by 10
Evaluation of Gene and Cell-Based Therapies for Cardiac Regeneration
Preda, M. B., & Valen, G. (2013) · Current Stem Cell Research & Therapy · doi:10.2174/1574888x11308040006 · Cited by 10
Current Advances in Vehicles for Brain Gene Delivery
Zhang, X., Zhao, L., Wu, J., Dong, H., Xu, F., Gong, G., & Hu, Y. (2012) · Current Gene Therapy · doi:10.2174/156652312802762590 · Cited by 11
Malerba, A., Sidoli, C., Lu‐Nguyen, N., Herath, S., Heron, A. L., Abdul-Razak, H. H., Jarmin, S., VandenDriessche, T., Chuah, M., Dickson, G., et al. (2021) · Human Gene Therapy · doi:10.1089/hum.2020.325 · Cited by 11
“10 11–13 A promising strategy to increase the transgene expression and therefore reduce the amount of vector to be delivered is optimizing the regulatory elements driving expression of the protein.”
Bergh, E. P., Buskmiller, C. M., & Johnson, A. (2021) · Obstetrics and Gynecology Clinics of North America · doi:10.1016/j.ogc.2021.06.004 · Cited by 11
Animal Models of Duchenne Muscular Dystrophy, with Special Reference to the mdx Mouse
Blain, A., Greally, E., Steve, L., Blamire, A. M., Guy, M., & Straub, V. W. (2012) · Journal of Applied Biomedicine · doi:10.1016/s0208-5216(12)70045-1 · Cited by 11
Characteristics of BAY 2599023 in the Current Treatment Landscape of Hemophilia A Gene Therapy
Pipe, S. W., Arruda, V. R., Lange, C., Kitchen, S., Eichler, H., & Wadsworth, S. C. (2022) · Current Gene Therapy · doi:10.2174/1566523222666220914105729 · Cited by 9
“As the capsid is the gene transfer vehicle, it has direct contact with the host environment and elicits an immune response [85].”
BackgroundYang, C., Yang, W., Chen, S., Bao-feng, M., Li, B., Lu, T., Qu, T., Klein, R. L., Zhao, L., & Duan, W. (2013) · PLoS ONE · doi:10.1371/journal.pone.0063876 · Cited by 9
Cho, J., Weinstein, D. A., & Lee, Y. (2020) · Journal of Inherited Metabolic Disease · doi:10.1002/jimd.12267 · Cited by 9
Essawi, K., Hakami, W., Khan, M. B. N., Martin, R., Zeng, J., Chu, R., Uchida, N., Bonifacino, A. C., Krouse, A. E., Linde, N. S., et al. (2023) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2023.04.004 · Cited by 9
Hahnewald, R., Wegner, W., & Reiss, J. (2009) · Genetic Vaccines and Therapy · doi:10.1186/1479-0556-7-9 · Cited by 9
In Utero Gene Therapy and Genome Editing
Hartman, H. A., Rossidis, A. C., & Peranteau, W. H. (2018) · Current Stem Cell Reports · doi:10.1007/s40778-018-0117-9 · Cited by 16
Vitale, F., Ortolan, J., Volpe, B., Marambaud, P., Giliberto, L., & d'Abramo, C. (2020) · Acta Neuropathologica Communications · doi:10.1186/s40478-020-01003-7 · Cited by 8
Advances in designing Adeno-associated viral vectors for development of anti-HBV gene therapeutics
Mnyandu, N., Limani, S. W., Arbuthnot, P. B., & Maepa, M. B. (2021) · Virology Journal · doi:10.1186/s12985-021-01715-9 · Cited by 9
Helper-Dependent Adenoviral Vectors
Brunetti‐Pierri, N., & Ng, P. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-800276-6.00017-6 · Cited by 10
Use of CD19-targeted immune modulation to eradicate AAV-neutralizing antibodies
Doshi, B. S., Markmann, C., Novak, N. C., Rojas, S. J., Davidson, R. J., Chau, J. Q., Wang, W., Carrig, S., Rus, C. M., Samelson‐Jones, B. J., et al. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.03.003 · Cited by 9
“41,42 These CD4 + T cells then recruit naive B cells to produce immunoglobulin M (IgM) and then class switch to IgG production.”
Mehta, N., Gilbert, R., Chahal, P. S., Moreno, M., Nassoury, N., Coulombe, N., Gingras, R., Mullick, A., Drouin, S., Sasseville, M., et al. (2025) · Gene Therapy · doi:10.1038/s41434-025-00524-x · Cited by 10
Vimalesvaran, S., Verma, A., Kyrana, E., Deheragoda, M. G., & Dhawan, A. K. (2023) · Clinical & Experimental Immunology · doi:10.1093/cei/uxad023 · Cited by 8
“This is evidenced by cases of hepatitis described in the early trials of AAV-2, when used as a viral vector for gene therapy, with a possible CD8+ cell-mediated response directed against the AAV-2 viral capsid (VP1) [11, 12].”
MethodChandra, S. A. M., Long, B. R., Fonck, C., Melton, A. C., Arens, J., Woloszynek, J. R., & O’neill, C. A. (2023) · Toxicologic Pathology · doi:10.1177/01926233231202995 · Cited by 8
“1,26,27 A cytotoxic T-cell response, either against the capsid proteins or the trans-gene itself, is likely to be manifested by hepatic inflammation or hepatic injury, with a concomitant increase in serum trans-aminases.”
BackgroundUnresolved Issues in RNA Therapeutics in Vascular Diseases With a Focus on Aneurysm Disease
Schellinger, I. N., Dannert, A., Mattern, K., Raaz, U., & Tsao, P. S. (2021) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.571076 · Cited by 8
“Additionally, they are less immunogenic than adenoviral vectors (96) and can be used for tissue-specific targeting (97).”
BackgroundShort-Term Steroid Treatment of Rhesus Macaque Increases Transduction
Yanda, M. K., Tomar, V., Cebotaru, C. V., Guggino, W. B., & Cebotaru, L. (2022) · Human Gene Therapy · doi:10.1089/hum.2021.239 · Cited by 8
Raissadati, A., Jokinen, J. J., Syrjälä, S. O., Keränen, M. A. I., Krebs, R., Tuuminen, R., Arnaudova, R., Rouvinen, E., Anisimov, A., Soronen, J., et al. (2013) · Transplant International · doi:10.1111/tri.12182 · Cited by 8
“It has previously been shown that AAV vectors may cause both host humoral and cellular immune reactions, in the form of viral capsid protein-specific neutralizing antibodies and CD8 cytotoxic T-cells targeted against virusinfected cells, respectively [39–43].”
BackgroundAdenoviral Vectors for Hemophilia Gene Therapy
Brunetti‐Pierri, N. (2013) · Journal of Genetic Syndromes & Gene Therapy · doi:10.4172/2157-7412.s1-017 · Cited by 9
“The source of immunogen has been attributed to AAV capsid peptides derived directly from the injected particles [51,53,54].”
BackgroundKomatsu, Y., Tanaka, C., Komorizono, R., & Tomonaga, K. (2020) · Scientific Reports · doi:10.1038/s41598-020-62630-7 · Cited by 9
Liu, H., Liu, N., Zhou, C., Du, A., Kapadia, M., Tai, P. W. L., Barton, E. S., Gao, G., & Wang, D. (2025) · EMBO Molecular Medicine · doi:10.1038/s44321-025-00248-w · Cited by 8
“…empty capsids can trigger or exacerbate capsid-directed immune responses, resulting in the clearance of transduced cells and further compromising therapeutic ef fi cacy (Hosel et al, 2012; Manno et al, 2006; Mingozzi et al, 2007; Nathwani et al, 2014; Schnodt and Buning, 2017; Wright, 2014).”
Najera, S. S., Nicastri, A., Bing, S. J., Sajib, A. M., Ternette, N., & Mazor, R. (2025) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2025.101506 · Cited by 9
Keselman, D. J., Small, J. C., Seneviratne, T., McCague, S., Kaschak, T. L., Yum, S. W., O'Brien, A., Brandsema, J. F., Diamond, T., Loomes, K. M., et al. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.10.007 · Cited by 11
Dargaud, Y. G., Yamaguti-Hayakawa, G. G., Frade-Guanaes, J. O., Leuci, A., & Ozelo, M. C. (2025) · Blood Reviews · doi:10.1016/j.blre.2025.101353 · Cited by 9
The HLA class I immunopeptidomes of AAV capsid proteins
Brito-Sierra, C. A., Lannan, M. B., Malherbe, L. P., & Siegel, R. W. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1212136 · Cited by 7
“Two of the highly conserved peptides, peptide 8 (VPQYGYLTL/ IPQYGYLTL) and peptide 9 (SQAVGRSSF), correspond to previously described immunogenic epitopes.”
BackgroundInfluentialGan, C., Leng, M., Liu, Y., Zheng, Z., He, S., Qiao, W., Lin, X., Xiao, Y., Ye, J., Zhou, L., et al. (2024) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2024.101399 · Cited by 7
Meierrieks, F., Rosario, J.-C., Rübeling, L., Asikoglu, H. C., Pflanz, K. B., Pickl, A., Kusch, K., Wolff, M. W., & Graf, B. (2025) · Journal of Chromatography A · doi:10.1016/j.chroma.2025.465674 · Cited by 7
PEG-mediated transduction of rAAV as a platform for spatially confined and efficient gene delivery
Zou, L., Wang, J., Fāng, Y., & Tian, H. (2022) · Biomaterials Research · doi:10.1186/s40824-022-00322-1 · Cited by 8
Montgomery, R., Monahan, P. E., & Ozelo, M. C. (2010) · Haemophilia · doi:10.1111/j.1365-2516.2010.02290.x · Cited by 7
Doherty, J. E., Woodard, L., Bear, A. S., Foster, A., & Wilson, M. H. (2013) · The FASEB Journal · doi:10.1096/fj.13-232090 · Cited by 11
Kuroda, M., Saitō, Y., Aso, M., & Yokote, K. (2018) · Chemical and Pharmaceutical Bulletin · doi:10.1248/cpb.c17-00786 · Cited by 7
VandenDriessche, T. (2009) · Blood · doi:10.1182/blood-2009-07-228510 · Cited by 7
Current regulatory requirements for assessment of immunogenicity for gene therapy medicinal products
Mann, C. J., Giblin, J., Braun, M., Schmid, F., Sørensen, M. R., Caferra, P., Hudák, A., Letoha, T., Coderch, N., Hickling, T. P., et al. (2025) · Cell Reports Medicine · doi:10.1016/j.xcrm.2025.102422 · Cited by 7
“8,55 Capsid-specific T cells normally display high cross-reactivity 8,84,85 and show a memory phenotype 84,86,87 but are not frequently detected in the peripheral blood.”
Liu, W., Pei, X., Yu, T., Xu, B., Dai, X., Xue, F., Chen, L., Wang, X., Wang, Y., Chen, Y., et al. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-026-02599-3 · Cited by 9
A platform to deliver single and bi-specific Cas9/guide RNA to perturb genes in vitro and in vivo
Li, Y., Chien, S., Huang, R., Herrmann, A., Zhao, Q., Li, P.-C., Zhang, C., Martincuks, A., Santiago, N. L., Zong, K., et al. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.07.025 · Cited by 9
AAV-mediated inner ear gene delivery triggers mild host immune responses in the mammalian inner ear
Ishibashi, Y., Zhu, J., Gernoux, G., Yu, Y., Suh, M. J., Isgrig, K. T., Grati, M., Olszewski, R. T., Hoa, M., Liang, C., et al. (2025) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2025.101456 · Cited by 9
“9,40,41 The human inner ear was previously considered to be immune privileged due to its relatively isolated anatomical location.”
Huang, X., Wang, X., Li, L., Qizhao, W., Xu, W., Wu, W., Xie, X., & Diao, Y. (2023) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.17858 · Cited by 6
Extracorporeal Delivery of rAAV with Metabolic Exchange and Oxygenation
Bieber, S. D., Halldorson, J. B., Finn, E. E., Ahmad, S., Chamberlain, J. S., & Odom, G. L. (2013) · Scientific Reports · doi:10.1038/srep01538 · Cited by 6
Gene therapy for inborn errors of liver metabolism: progress towards clinical applications
Brunetti‐Pierri, N. (2008) · The Italian Journal of Pediatrics/Italian journal of pediatrics · doi:10.1186/1824-7288-34-2 · Cited by 7
Zarbin, M. A., Leary, J. F., Montemagno, C. D., Ritch, R. H., & Humayun, M. S. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4557-0737-9.00036-9 · Cited by 7
Vector Decoys Trick the Immune Response
VandenDriessche, T., & Chuah, M. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3006633 · Cited by 6
Yamahira, A., Narita, M., Ishii, K., Jayathilake, R. M. C., Iwabuchi, M., Satoh, N., Uchiyama, T., Taniguchi, T., Hashimoto, S., Kasahara, N., et al. (2012) · Leukemia Research · doi:10.1016/j.leukres.2012.09.002 · Cited by 6
Gene Therapy in Pediatric Liver Disease
Muro, A. F., D’Antiga, L., & Mingozzi, F. (2019) · Springer eBooks · doi:10.1007/978-3-319-96400-3_44 · Cited by 7
Self-citationFactor IX Padua for haemophilia B gene addition: universal adaptation and repeated success
George, L. A. (2022) · The Lancet Haematology · doi:10.1016/s2352-3026(22)00178-8 · Cited by 6
Adeno‐associated Viral Vectors in Gene Therapy
Ling, C., Zhong, L., & Srivastava, A. (2018) · Wiley eBooks · doi:10.1002/9780470015902.a0005738.pub3 · Cited by 6
Grubor, B., Henry, K. L., Chan, S. J., Sheehan, M. J., Shah, A., Pellerin, A., Bai, J., Nadella, P., Bommegowda, S., Cullen, P. F., et al. (2025) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2025.101643 · Cited by 6
Zhang, T., & Zou, P. (2023) · The AAPS Journal · doi:10.1208/s12248-023-00867-6 · Cited by 5
Ex vivo gene editing and cell therapy for hereditary tyrosinemia type 1
Ates, I., Stuart, C., Rathbone, T., Barzi, M., He, G., Major, A. M., Shankar, V., Lyman, R. A., Angner, S. S., Mackay, T. F. C., et al. (2024) · Hepatology Communications · doi:10.1097/hc9.0000000000000424 · Cited by 6
“[10] 18] Modification of the AAV capsid has been proposed to overcome AAV immunity risks, but safety concerns still remain.”
Gomes, C. M., Sebastião, M. J., Silva, G. P. D. L., Moura, F., Simão, D. F., Gomes‐Alves, P., Alves, P. M., & Brito, C. (2024) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2024.1379597 · Cited by 5
AAV Vector-Based Gene Therapy, Progress and Current Challenges
Kuranda, K., & Mingozzi, F. (2017) · Springer eBooks · doi:10.1007/978-3-319-53457-2_5 · Cited by 5
Self-citationTargeting Age-Related Neurodegenerative Diseases by AAV-Mediated Gene Therapy
Cagin, U. (2021) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-55035-6_15 · Cited by 5
Prenatal Gene Therapy for Metabolic Disorders
Coons, B. E., & Peranteau, W. H. (2021) · Clinical Obstetrics & Gynecology · doi:10.1097/grf.0000000000000662 · Cited by 7
Approved gene therapies in Australia: coming to a store near you
Mallik, S., Bailey, C. G., & Rasko, J. E. J. (2022) · Internal Medicine Journal · doi:10.1111/imj.15880 · Cited by 5
Self-citationMasri, S., Carré, L., Jaulin, N., Vandamme, C., Couzinié, C., Guy‐Duché, A., Dupont, J.-B., Pereira, A., Charpentier, É., David, L., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241310447 · Cited by 6
Molecular characterization of novel Adeno-associated virus variants infecting human tissues
Purohit, N., Jain, A., Mathews, V., & Jayandharan, G. R. (2019) · Virus Research · doi:10.1016/j.virusres.2019.197716 · Cited by 5
Gene Therapy in Cystic Fibrosis
Prickett, M. H., & Jain, M. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-800563-7.00016-6 · Cited by 5
Moving Forward Toward a Cure for Hemophilia B
VandenDriessche, T., & Chuah, M. (2015) · Molecular Therapy · doi:10.1038/mt.2015.56 · Cited by 5
Rasko, J. E. J. (2010) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2010.06313.x · Cited by 5
Self-citationGeorge, L. A. (2021) · Blood · doi:10.1182/blood.2020009285 · Cited by 6
Ramella Gal, I., Arez, F., Correia, I. P., Domenici, G., Fernandes, S., Silva, G., Saldanha, I., Duarte, N., Freitas, C., Alves, P. M., et al. (2025) · Scientific Reports · doi:10.1038/s41598-025-31044-8 · Cited by 4
“However, despite their expected low immunogenicity, liver-296 directed transduction with rAAVs has been hindered by unpredicted immune responses mediated by neutralizing antibodies (humoral immunity) and CD8+ T-cells (adaptive immunity)[16], [17] .”
Dou, D., Lu, J., Chen, X., & Zhang, X. (2025) · Pharmaceutical Research · doi:10.1007/s11095-025-03931-2 · Cited by 4
mGem: AAV, from almost a virus to an awesome vector—or is it?
Srivastava, A. (2026) · mBio · doi:10.1128/mbio.02957-25 · Cited by 5
“…(67), and threonine (68) residues, which serves as a signal for ubiquitination at lysine (69) residues, followed by proteasome-mediated degradation (70, 71), which negatively impacts not only on the transduction efficiency, but the broken down peptides also trigger a cytotoxic T-cell response (72).”
Bing, S., Eskandarian, A., Smith, S., Sajib, A. M., Warrington, S., Saleh, S., Najera, S. S., D'Esposito, R., Santana-Quintero, L. V., & Mazor, R. (2026) · Nature Communications · doi:10.1038/s41467-026-69917-9 · Cited by 4
Bing, S. J., Warrington, S., & Mazor, R. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1211529 · Cited by 4
Cell Therapies and Gene Therapy for Diabetes: Current Progress
Ghassemifard, L., Hasanlu, M., Parsamanesh, N., Atkin, S. L., Almahmeed, W. A., & Sahebkar, A. (2024) · Current Diabetes Reviews · doi:10.2174/0115733998292392240425122326 · Cited by 4
Recent developments in translational imaging of in vivo gene therapy outcomes
Day, I. L., Tamboline, M., Lipshutz, G. S., & Xu, S. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.12.049 · Cited by 5
“198,206,207 Non-invasive imaging biomarkers have been developed for monitoring liver injury and failure, such as 18 F-2-deoxy-2-fl uoroarabinose for PET imaging.”
Rapti, K., Hajjar, R. J., & Weber, T. (2012) · Humana Press eBooks · doi:10.1007/978-1-61779-891-7_12 · Cited by 4
Viral Vectors for Delivery of Antiviral Sequences
Arbuthnot, P. B. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-410518-8.00004-1 · Cited by 4
Wang, Q., Zhang, L., Zhang, G., Mao, J.-H., Xi, X., Jiang, L., Lv, G., Lu, J., Shen, Y., Chen, Z., et al. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2110887118 · Cited by 4
In Utero Fetal Therapy: Stem Cells, Cell Transplantation, Gene Therapy, and CRISPR-Cas9
Shear, M. A., & Massa, A. (2021) · Clinical Obstetrics & Gynecology · doi:10.1097/grf.0000000000000663 · Cited by 6
Challenges to Gene Editing Approaches in the Retina
Bonillo, M., Pfromm, J. K., & Fischer, M. D. (2022) · Klinische Monatsblätter für Augenheilkunde · doi:10.1055/a-1757-9810 · Cited by 6
Metadata
- Authors
- Mingozzi, F., Maus, M. V., Hui, D. J., Sabatino, D. E., Murphy, S. L., Rasko, J. E. J., Ragni, M. V., Manno, C. S., Sommer, J., Jiang, H., Pierce, G. F., Ertl, H. C. J., & High, K. A.
- Affiliations
- Children's Hospital of Philadelphia (US)
- The University of Sydney (AU)
- Hemophilia Center of Western Pennsylvania (US)
- The Wistar Institute (US)
- Corresponding author
- High, Katherine A
- ORCID
- Venue
- Nature Medicine
- Published
- 2007-03-18
- Volume
- 13
- Issue
- 4
- Pages
- 419-422
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- OpenAlex
- W2007261697
- Cited by
- 748
- References
- 8
- Citations by year
- 2026: 34 · 2025: 43 · 2024: 43 · 2023: 41 · 2022: 34 · 2021: 58 · 2020: 43 · 2019: 40 · 2018: 28 · 2017: 38 · 2016: 24 · 2015: 40 · 2014: 41 · 2013: 37 · 2012: 40
- FWCI
- 22.15
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (1f32hl069647-01)
- National Heart, Lung, and Blood Institute (F32 HL69647, P01HL078810, T32HL007439)
- National Institute of Allergy and Infectious Diseases (P30AI045008)
- National Institute of Diabetes and Digestive and Kidney Diseases (T32DK007748)
- National Center for Research Resources (M01RR000056, M01RR000240)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- adeno-associated virus, AAV capsid, CD8+ T cells, AAV serotype 2, gene transfer, T cell memory, T cell proliferation
- MeSH terms
- Dependovirus, Animals, Capsid, Humans, Lymphocyte Activation, Parvoviridae Infections, Peptides, Gene Transfer Techniques, CD8-Positive T-Lymphocytes, Hepatocytes, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.